The Inventing Press

Cigna Group

Financial highlights

MetricFY 12/31/25FY 12/31/24FY 12/31/23FY 12/31/22FY 12/31/21
Income Statement
Revenue$274.9B$247.1B$195.3B$180.5B$174.1B
Selling, general & administrative$14.6B$14.8B$14.8B$13.2B$13.0B
Operating income$9.2B$9.4B$8.5B$8.4B$7.9B
Pretax income$7.8B$5.3B$5.5B$8.4B$6.8B
Income tax expense$1.5B$1.5B$141.0M$1.6B$1.4B
Net income$6.0B$3.4B$5.2B$6.8B$5.4B
Balance Sheet
Cash and equivalents$7.7B$7.5B$7.8B$5.9B$5.1B
Current assets$47.8B$48.9B$37.4B$30.1B$36.1B
Total assets$157.9B$155.9B$152.8B$143.9B$154.9B
Current liabilities$56.3B$58.0B$48.7B$41.2B$43.6B
Total liabilities$116.0B$114.6B$106.4B$99.1B$107.7B
Stockholders' equity$41.7B$41.0B$46.2B$44.7B$47.1B
Cash Flow Statement
Cash from operations$9.6B$10.4B$11.8B$8.7B$7.2B
Depreciation and amortization$2.8B$2.8B$3.0B$2.9B$2.9B
Stock-based compensation$291.0M$308.0M$286.0M$264.0M$268.0M
Dividends paid$1.6B$1.6B$1.4B$1.4B$1.3B
Share repurchases$3.6B$7.0B$2.3B$7.6B$7.7B

Shares outstanding 264.5M · Free float 99.4%

Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.

Recent filings

  • May 13, 2026 8-K
  • April 30, 2026 10-Q
  • April 30, 2026 8-K
  • April 27, 2026 8-K
  • March 3, 2026 8-K
  • February 27, 2026 8-K
  • February 26, 2026 10-K
  • February 5, 2026 8-K